Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04626778 · ClinicalTrials.gov registry record · Phase 2

Clinical Efficacy of Single-Use of Peroxyl Mouthwash for Reducing Bacteria in Saliva and Bioaerosol Contamination

A Phase 2 study, sponsored by Colgate Palmolive.

Completed
Registry status
Phase 2
Development phase
100
Enrollment target

NCT04626778: Completed Phase 2 study, sponsored by Colgate Palmolive.

NCT04626778 is a Phase 2 study that has completed, run by Colgate Palmolive. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04626778, a Phase 2 study, has completed, sponsored by Colgate Palmolive.

COMPLETED
Registry status
Phase 2
Development phase
100 participants
Enrollment target

Study Summary

To evaluate the anti-bacterial, pre-procedural, clinical efficacy of Peroxyl mouthwash (1.5% hydrogen peroxide) in saliva and the reduction of bioaerosol contamination as compared to a matching placebo mouthwash (0.0% hydrogen peroxide)

Primary Outcome

Saliva samples will be collected from participants prior to rinsing with their assigned mouthwash (1.5% hydrogen peroxide or 0.0% hydrogen peroxide) for one minute and then expectorate. Saliva samples will again be collected immediately after, at 30 min, and 60 min after rinsing. All collected saliva samples will be placed in sterile vials, labeled with subject information and transferred to the microbiology laboratory for analysis.

Interventions

  • DRUG Peroxyl Mouthwash
  • DRUG Placebo Mouthwash

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2020-10-08
Est. Completion 2020-12-15
Phase Phase 2
Colgate Palmolive

51 total trials

What the finished NCT04626778 record still lists

NCT04626778 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).

The record links to 0 conditions, and to 2 interventions - of which Peroxyl Mouthwash is the first listed.

NCT04626778 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04626778 about?

NCT04626778 is a clinical study titled "Clinical Efficacy of Single-Use of Peroxyl Mouthwash for Reducing Bacteria in Saliva and Bioaerosol Contamination". To evaluate the anti-bacterial, pre-procedural, clinical efficacy of Peroxyl mouthwash (1.5% hydrogen peroxide) in saliva and the reduction of bioaerosol contamination as compared to a matching placebo mouthwash (0.0% hydrogen peroxide)

What is the current status of trial NCT04626778?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-10-08. Estimated completion is 2020-12-15.

What interventions are being tested in trial NCT04626778?

The interventions under investigation include: Peroxyl Mouthwash (DRUG), Placebo Mouthwash (DRUG).

Who is sponsoring clinical trial NCT04626778?

This trial is sponsored by Colgate Palmolive, which has 51 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04626778's enrollment target sits among peer trials

100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04626778, the US trial registry maintained by the National Library of Medicine. NCT04626778 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.